Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omeros Debuts With $68 Million IPO Despite Legal Hassles From Former CFO

Executive Summary

Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range

You may also be interested in...



Is Ironwood The IPO Medicine To Get Things Moving?

Ironwood Pharmaceuticals' $188 million IPO was like the proverbial elephant among the blind men. How you perceived it depended upon where you touched it

Venture Investment Plummets In 2009 As VCs Retrench

Last year was the worst on record since 1997 for venture investment. VCs hold out hope, however, as deal volume and committed dollars increased from Q3 to Q4.

Venture Investment Plummets In 2009 As VCs Retrench

Last year was the worst on record since 1997 for venture investment. VCs hold out hope, however, as deal volume and committed dollars increased from Q3 to Q4.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel